NeuroSync
NeuroSync develops an FDA-cleared, VR-based eye tracking platform that uses proprietary algorithms to assess brain health and diagnose concussion, serving healthcare providers, sports organizations, military, and biopharma customers across the US and EU.
- Company typePrivate
- Founded2015
- HeadquartersHolliston, United States
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What NeuroSync does
NeuroSync, Inc. (formerly SyncThink) is a privately held digital health company founded in 2015 by neurosurgeon Dr. Jam Ghajar, headquartered in Holliston, Massachusetts with additional offices in Boston and a technology presence in Palo Alto. The company develops a VR-based eye tracking platform that uses proprietary algorithms — developed over more than 15 years of clinical research and protected by 16 patents — to record, analyze, and quantify eye movement patterns as objective biomarkers for neurological conditions, most notably concussion. Its flagship product, EYE-SYNC, is an FDA-cleared (510(k) 2016, Breakthrough Device Designation 2019, concussion diagnosis clearance 2021), CE Mark-certified (2022) wireless VR system that completes assessments in under 60 seconds, integrates with EMR systems via REST API, and stores data in HIPAA-compliant cloud infrastructure. PRO-SYNC, launched in 2022, extends the underlying technology into consumer brain performance and wellness monitoring via a mobile app, while the NeuroSync Management Portal (October 2023) provides a web-based administrative layer for provider workflows.
The company sells EYE-SYNC as a bundled hardware-plus-software solution (Pico Neo 3 Pro Eye VR headset, Samsung tablet, proprietary analytics software, EMR integration) under multi-year enterprise contracts with quote-based pricing, supplemented by provider training and certification, clinical trial services for CNS drug development, and recurring software/cloud subscription. Go-to-market is enterprise field sales targeting four primary verticals: healthcare providers (hospitals and clinics such as Massachusetts General Hospital, Texas Medical Center, Houston Methodist, Sutter Health, and Barnabas Health), collegiate and professional sports organizations (Rice University, Georgia Tech, Virginia Tech), military and Department of Defense buyers, and biopharma companies running CNS clinical trials. The platform has been deployed to 5,188 clinicians and used for 405,000 patient assessments, generating a proprietary dataset of over 1.57 billion data points. Distribution is enabled through hardware partnerships with Pico Interactive and Tobii, with an expanding relationship with Magic Leap for future AR-based product development. The company is led by Chairman, CEO and President Gary L. Gregory, who has led multiple healthcare startups including an IPO at NeuroMetrix. In May 2025, the FDA's Center for Devices and Radiological Health issued a warning letter to NeuroSync for design control failures on the EYE-SYNC device.
NeuroSync firmographics
Firmographics- Name
- NeuroSync
- Legal name
- NeuroSync Inc.
- Website
- https://neurosync.health
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- NeuroSync develops an FDA-cleared, VR-based eye tracking platform that uses proprietary algorithms to assess brain health and diagnose concussion, serving healthcare providers, sports organizations, military, and biopharma customers across the US and EU.
- Ownership category
- akta.pro rank
NeuroSync industry classification
Industry- Product category
- Digital Neurological Diagnostics
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables) (HLAHACAE)
- akta.pro secondary industries
- Behavioral Health & Neurocognitive Therapeutics (Digital) (HLACANAI), Neurology RPM (epilepsy, Parkinson’s, MS monitoring) (HLALAFAJ)
Keywords
Where NeuroSync is headquartered
LocationHeadquarters
- HQ city
- Holliston
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
NeuroSync business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Operations, Supply Chain
Revenue model
- Hardware Sales: Sale of EYE-SYNC system including VR headset (Pico Neo 3 Pro Eye), Samsung tablet, carrying case, and customizable battery. Pricing not publicly disclosed, requires contact for quote.
- Software/Subscription: Software licensing for proprietary eye tracking analytics and assessment battery. Includes secure, HIPAA compliant cloud data storage.
- Training and Certification: Initial training and onboarding for providers on platform use, administration, and result interpretation. Certification provided upon completion.
- Clinical Trial Services: CNS drug trials support with quantifiable biomarkers for pharmaceutical companies, working as both CRO and technology provider.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Hybrid | Multi-year contract | EYE-SYNC Complete System |
Go-to-market motion2 records
Distribution channels2 records
Marketing channels5 records
NeuroSync product offering
Product offeringCore offering
NeuroSync provides a digital health platform that assesses brain health through VR-based eye tracking technology. The core offering is EYE-SYNC, an FDA-cleared system combining a wireless VR headset with proprietary analytics software to record and analyze eye movements as an aid to concussion diagnosis and visual impairment identification, completing assessments in under 60 seconds. A secondary offering, PRO-SYNC, delivers brain performance monitoring via a mobile application that scores sleep quality and mental acuity for readiness and performance optimization.
Product overview
NeuroSync offers a platform of brain health assessment and performance optimization products centered around its FDA-cleared EYE-SYNC VR-based eye tracking system. EYE-SYNC serves as the core clinical product for concussion diagnosis and visual impairment assessment, while PRO-SYNC extends reach to consumer brain performance monitoring via mobile app. The platform integrates hardware (VR headset and tablet), proprietary analytics software, customizable reporting, and EMR/API connectivity into a unified solution for healthcare, sports, military, and biopharma markets.
Differentiator
Problem solved
Functional benefit
Brands
- EYE-SYNC: FDA-cleared virtual reality eye-tracking headset and assessment platform for concussion diagnosis and brain health evaluation.
- PRO-SYNC
- NeuroSync Management Portal
Products and services
- EYE-SYNC FDA-cleared VR-based eye tracking platform for concussion diagnosis and visual impairment identification. Uses proprietary algorithms to record, analyze, and quantify eye movements as an aid to concussion diagnosis. Assessments complete in under 60 seconds and provide actionable, objective data to clinicians. Targeted at healthcare providers, sports organizations, military, and biopharma clients.
- PRO-SYNC Mobile brain performance monitoring application for sleep quality and mental acuity assessment. Screens timing, working memory, attention, inhibitory control, and concentration in under 60 seconds per assessment. Provides 1-100 readiness scores and trend monitoring. General wellness product, not FDA cleared as a medical device.
- EYE-SYNC Hardware Package Complete hardware bundle including Pico Neo 3 Eye wireless VR headset, Samsung S10 Android Tablet, protective carrying case, customizable battery, EMR integration, and HIPAA-compliant cloud storage. Wireless, Bluetooth-enabled system for portable patient assessments sold as part of the EYE-SYNC complete system.
Quantifiable outcome
- 0.9 test-retest reliability
- +3 more outcomes
Companies that use NeuroSync
Customer profileNamed customers13 records
Segments5 records
Ideal customer profiles4 records
NeuroSync technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- Yes
- API docs
- API detail
Core technology
AI maturity
App detail
Integration2 records
AI capability4 records
Feature8 records
NeuroSync partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core and secondary.
- Pico InteractivecorePico Interactive provides the Neo 3 Pro Eye VR headset integrated with NeuroSync's EYE-SYNC technology. This partnership enables the wireless, Bluetooth-enabled VR platform for eye tracking assessments. The partnership was formed in 2021 and represents the third generation of hardware integration.
- TobiicoreTobii provides eye tracking technology and Tobii Ocumen middleware for the EYE-SYNC platform. Tobii's high-level filters process raw eye tracking data into reliable biomarkers, enabling NeuroSync's analysis. This partnership dates to the third generation EYE-SYNC launch in 2020-2021.
- Magic LeapsecondaryNeuroSync is expanding its working relationship with Magic Leap for AR technology. The partnership is expected to enable additional product solutions in the AR space. Expanded partnership announced in late 2021.
Scale indicators10 records
Recent moves7 records
Expansion highlights6 records
NeuroSync competitors and assessment
Company assessmentBroad incumbents
- ImPACT Applications: ImPACT Applications is the established incumbent in concussion baseline and post-injury testing, used across professional and collegiate sports. While its core modality is neurocognitive testing rather than eye-tracking, it competes for the same sports medicine and clinical concussion assessment budgets.
- Posit Science: Posit Science develops computerized cognitive training and assessment tools (BrainHQ) used in clinical research and brain performance. It is a broader incumbent in digital brain health with overlapping cognitive assessment capabilities, though without NeuroSync's hardware-based eye-tracking modality.
Direct peers
- C3 Logix: C3 Logix delivers a multi-modal concussion assessment platform combining balance, cognitive, and visual tracking. It targets the same healthcare and sports customers as NeuroSync with comparable objective concussion evaluation capabilities.
- HeadCheck Health: HeadCheck Health offers a concussion management platform for sports organizations, integrating symptom evaluation, balance, and cognitive testing. It competes with NeuroSync for sports medicine and athletic training room deployments.
- RightEye: RightEye uses eye-tracking technology to assess brain and visual health, including concussion and neurological conditions. It is the closest direct competitor to NeuroSync's EYE-SYNC, serving similar clinical and sports customers with objective eye-movement biomarkers.
- Oculogica: Oculogica develops the EyeBOX, an FDA-cleared eye-tracking device for concussion and traumatic brain injury assessment. It competes head-to-head with EYE-SYNC in objective concussion diagnostics for clinicians and sports programs.
- Sway Medical: Sway Medical provides mobile-based balance and cognitive assessment tools widely used in concussion management across collegiate and professional sports. It is a directly comparable, technology-driven concussion assessment solution targeting similar sports medicine customers.
Emerging players
- MindMaze: MindMaze combines VR, AI, and neuroscience for neurological assessment and rehabilitation across stroke, TBI, and other indications. It is an emerging player that overlaps with NeuroSync in VR-based brain health, particularly in rehabilitation and performance use cases.
- Cambridge Brain Sciences: Cambridge Brain Sciences provides digital cognitive assessment tools used in clinical research, healthcare, and consumer wellness. It is an emerging player in objective brain health measurement, partially overlapping with PRO-SYNC's cognitive monitoring use cases.
Others
- NovaBay Pharmaceuticals: While primarily an ophthalmic pharmaceutical company, NovaBay is referenced as a peripheral adjacency because of NeuroSync's vision/eye-tracking focus and the overlap between neuro-ophthalmic diagnostics and broader eye health markets.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
NeuroSync social profiles
Digital presenceNeuroSync compliance and trust
Trust signalCompliance3 records
NeuroSync financial estimates
Financial estimateRevenue estimate
Valuation estimate
NeuroSync leadership team
Management profileNumber of profiles
Profiles6 records
NeuroSync funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
NeuroSync M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about NeuroSync
What does NeuroSync do?
NeuroSync provides a digital health platform that assesses brain health through VR-based eye tracking technology. The core offering is EYE-SYNC, an FDA-cleared system combining a wireless VR headset with proprietary analytics software to record and analyze eye movements as an aid to concussion diagnosis and visual impairment identification, completing assessments in under 60 seconds. A secondary offering, PRO-SYNC, delivers brain performance monitoring via a mobile application that scores sleep quality and mental acuity for readiness and performance optimization.
Is NeuroSync a public or private company?
NeuroSync is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was NeuroSync founded?
NeuroSync was founded in 2015. It employs 11 to 50 people.
Where is NeuroSync based?
NeuroSync is headquartered in Holliston, United States, in the North America region.
How does NeuroSync make money?
Four revenue lines are on record. Hardware Sales are the primary driver. The others are software/Subscription, training and Certification and clinical Trial Services.
Who are NeuroSync's main competitors?
Broad incumbents on record are ImPACT Applications and Posit Science. Direct peers are C3 Logix, HeadCheck Health, RightEye, Oculogica and Sway Medical. Emerging players are MindMaze and Cambridge Brain Sciences. NovaBay Pharmaceuticals is listed as an others.
Does NeuroSync have an API?
Yes. NeuroSync offers a REST API for data export to EMR systems and other databases. The API enables secure data transfer of assessment results to Electronic Medical Records or athlete management systems. Results can also be exported via PDF through the API. The API is included with the product package and supports HIPAA-compliant cloud storage.
What industry is NeuroSync in?
NeuroSync's product category is Digital Neurological Diagnostics. Its primary akta.pro industry code is HLAHACAE, Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables), with a secondary code of HLACANAI, Behavioral Health & Neurocognitive Therapeutics (Digital). Its NAICS code is 334510 and its SIC code is 3845.